
    
      Efficacy evaluation:

      Primary efficacy index:

      After 12 weeks of treatment, the change of arteriosclerosis related biomarker in 4 modality
      groups, comparing with the base line information

      Secondary efficacy index:

      After 8 weeks of treatment, the change of arteriosclerosis related biomarker in 4 modality
      groups, comparing with the base line information

      Safety evaluation:

        1. Adverse Event

        2. Vital Sign and Physical Examination

        3. 12-lead ECG

        4. Laboratory Tests (including blood routine examination, routine urine analysis, blood
           biochemistry examination, glycosylated hemoglobin)
    
  